The verdict
Our read at a glance.
Whether persistent side effects after stopping are a real syndrome or a nocebo artefact, and what that means for a healthy man taking it for hair.
- The signal
- The efficacy evidence is extensive and long-running: large randomized trials and years of post-marketing data support finasteride for androgenetic alopecia and benign prostatic hyperplasia, with a substantial trial literature also covering prostate cancer prevention and its interpretation. The contested area is different in kind. Reports of sexual dysfunction, depression and cognitive complaints persisting after discontinuation have accumulated to the point where labelling has been revised in multiple jurisdictions to reflect reports of persistent sexual dysfunction and of depression and suicidal ideation, while the underlying causal question remains genuinely unsettled in the literature.
- The unknown
- Whether persistent post-finasteride symptoms represent a real, mechanistically explicable syndrome in a susceptible minority, and if so who is susceptible. Observational designs cannot separate this cleanly from expectation effects and confounding by the distress of hair loss itself.
- Our read
- An effective drug with real outcome data and a genuinely unresolved harm signal - a combination this Watchlist does not often get to state so plainly. The honest position is neither dismissal nor alarm: the effect on hair is proven, the persistence question is open, and it is being taken indefinitely by healthy men for a cosmetic indication, which raises the bar on what an unresolved question is worth.
The mechanism
How it works.
Testosterone is converted into dihydrotestosterone by 5-alpha-reductase, and dihydrotestosterone binds the androgen receptor several times more avidly than testosterone does. In genetically susceptible scalp follicles that signal drives miniaturisation, and in the prostate it drives growth. Finasteride inhibits the type II isoform of the enzyme, cutting circulating dihydrotestosterone substantially and scalp levels further, which halts miniaturisation in a large proportion of men. The reason the safety debate is not absurd is that 5-alpha-reductase does more than make dihydrotestosterone. The same enzyme family is required to produce neurosteroids such as allopregnanolone, which modulates GABA-A receptors in the brain. That gives a plausible mechanistic route by which inhibiting the enzyme could affect mood and sexual function centrally, which is why the persistent-symptom hypothesis has not been dismissed outright.
Safety & regulatory boundary
The consequential part.
Approved for androgenetic alopecia and benign prostatic hyperplasia. Labels carry sexual adverse effects and, following regulatory review, information about depression and suicidal ideation and reports of persistent sexual dysfunction after discontinuation. It suppresses dihydrotestosterone systemically, not just at the scalp, and it lowers prostate-specific antigen, which matters for cancer screening interpretation. It is teratogenic in male fetuses and women who are or may become pregnant must not handle broken tablets. Prohibited in sport historically as a masking agent, though it has since been removed from that list.
What's next
What we're watching.
Prospective work with pre-specified psychiatric and sexual endpoints, which is the only design that can settle the persistence question.
Context
Why this is discussed.
It is the most effective non-surgical treatment for male pattern hair loss, it is taken by men who are otherwise healthy, often for decades, and it is standard in the strength world for managing androgen-driven hair loss.
The evidence base
23 cited references.
Regulatory & labels3
Camber Pharmaceuticals, Inc. (FDA label) · 2017
Rising Pharma Holdings, Inc. (FDA label) · 2024
REMEDYREPACK INC. (FDA label) · 2026
Registered trials8
ClinicalTrials.gov · PHASE2/PHASE3 · NOT_YET_RECRUITING · 2027-10-01
ClinicalTrials.gov · PHASE4 · NOT_YET_RECRUITING · 2026-08-31
ClinicalTrials.gov · PHASE4 · COMPLETED · registry record
ClinicalTrials.gov · ACTIVE_NOT_RECRUITING · 2019-10-16
ClinicalTrials.gov · NA · ENROLLING_BY_INVITATION · 2026-01-01
ClinicalTrials.gov · NA · NOT_YET_RECRUITING · 2026-06-01
ClinicalTrials.gov · PHASE2 · RECRUITING · 2025-12-03
ClinicalTrials.gov · PHASE3 · RECRUITING · 2026-04
Indexed literature (PubMed)12
Gupta AK et al. · J Dermatolog Treat · 2022
Gupta AK et al. · J Dermatolog Treat · 2022
Piraccini BM et al. · J Eur Acad Dermatol Venereol · 2022
Pompili M et al. · J Clin Psychopharmacol · 2021
Fertig RM et al. · Dermatol Online J · 2017
Gupta AK et al. · J Cosmet Dermatol · 2022
Romero Pérez P · Arch Esp Urol · 2022
Kaufman KD et al. · J Am Acad Dermatol · 1998
Chaudhary UB et al. · Expert Opin Drug Metab Toxicol · 2010
Drake L et al. · J Am Acad Dermatol · 1999
Rossi A et al. · Int J Immunopathol Pharmacol · 2012
Motofei IG et al. · J Dermatolog Treat · 2020
Keep reading